Neuronetics outlines 2026 revenue of $160M-$164M while shifting NeuroStar to broader ownership models (NASDAQ:STIM)
Neuronetics (STIM) Q2 2026 earnings call: revenue +9%, margin expansion, lower OPEX, updated guidance, and NeuroStar leasing shift.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Neuronetics (STIM) Q2 2026 earnings call: revenue +9%, margin expansion, lower OPEX, updated guidance, and NeuroStar leasing shift.
Neuronetics outlines 2026 revenue of $160M-$164M while shifting NeuroStar to broader ownership models (NASDAQ:STIM) | Seeking Alpha
Earnings Call Insights: Neuronetics (STIM) Q2 2026
Management View
"I'm pleased to report the second quarter began to reflect our steady execution against the goals I cited last quarter. Total revenue was $41.6 million, up approximately 9% versus the second quarter of last year" (CEO, President & Director
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Quick Insights
How is Neuronetics' shift to new commercial models impacting revenue and growth?
Broadening commercial options (outright purchase, lease) shifts revenue mix away from session-only, elevating capital, consumables, and service revenue, with potential near-term choppiness but positioning for sustained long-term growth.
What drove Neuronetics' improved gross margin and cost reductions this quarter?
Gross margin gains stemmed from revenue cycle enhancements, especially at Greenbrook, better payer workflow, and a favorable NeuroStar product mix, while operating costs fell due to ongoing expense management and process improvements.
What risks and forward guidance did Neuronetics outline for the remainder of the year?
The company narrowed revenue guidance, raised gross margin, lowered OPEX, and cautioned on potential 2H revenue volatility due to evolving commercial model, with an updated cash outflow forecast of negative $10.5M to $14.5M as reporting transparency will decrease with segment aggregation.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Enterprises focused on ROI, but AI spending remains strong: UBS
UBS said enterprises are optimizing AI tokens for better ROI while spending stays strong.
Organigram surges 10% on record Q3 results (OGI:NASDAQ)
Organigram Global (OGI) shares jump after record Q3 revenue & EBITDA, boosted by Sanity Group acquisition and margin gains.
Anthropic models released in EU now embed watermarks on all AI-generated content
Anthropicâs Claude models in the EU will embed watermarks and provenance metadata under the EU AI Act Article 50âsee what changes Aug. 2, 2026.
Altius Minerals Raises Quarterly Dividend 10% to C$0.11, Extending Growth Streak and Signaling Cash Flow Confidence
Altius Minerals increases its quarterly dividend by 10% to C$0.11 per share, continuing its multi-year growth record. This article analyzes its business model, financial health, and industry trends, exploring shareholder return strategies and potential risks for royalty companies.